Hong Kong Pharmaceuticals & Biotech High Growth Potential Companies

RemeGen

Market Cap: HK$22.7b

A biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States.

Akeso

Market Cap: HK$73.8b

A biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs.

WuXi XDC Cayman

Market Cap: HK$40.4b

An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.

Ocumension Therapeutics

Market Cap: HK$3.9b

Operates as an ophthalmic pharmaceutical platform company in the People's Republic of China.

Ascentage Pharma Group International

Market Cap: HK$12.7b

A clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China.

Sichuan Kelun-Biotech Biopharmaceutical

Market Cap: HK$68.6b

A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs to address unmet medical needs in the People’s Republic of China and internationally.

Everest Medicines

Market Cap: HK$15.7b

A biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.

Alphamab Oncology

Market Cap: HK$6.1b

A clinical stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of oncology biologics.

CanSino Biologics

Market Cap: HK$10.7b

Develops, manufactures, and commercializes vaccines in the People’s Republic of China.

Cutia Therapeutics

Market Cap: HK$1.4b

An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong.

Innovent Biologics

Market Cap: HK$78.2b

A biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China.

Consun Pharmaceutical Group

Market Cap: HK$7.8b

Researches and develops, manufactures, and sells Chinese medicines and medical contrast medium products in the People’s Republic of China.

Frontage Holdings

Market Cap: HK$2.4b

A contract research organization, provides laboratory and related services to pharmaceutical, biotechnology, and agrochemical companies.

Luye Pharma Group

Market Cap: HK$6.8b

An investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide.

Essex Bio-Technology

Market Cap: HK$2.4b

An investment holding company, develops, manufactures, and sells biologic drugs in the People’s Republic of China, Hong Kong, and internationally.

CStone Pharmaceuticals

Market Cap: HK$3.1b

A biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally.

Genscript Biotech

Market Cap: HK$22.5b

An investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally.

Simcere Pharmaceutical Group

Market Cap: HK$20.1b

Engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China.

Viva Biotech Holdings

Market Cap: HK$2.8b

An investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide.

3SBio

Market Cap: HK$29.2b

An investment holding company, develops, produces markets, and sells biopharmaceutical products in Mainland China and internationally.

JBM (Healthcare)

Market Cap: HK$1.6b

An investment holding company, engages in the manufacture, marketing, distribution, and sale of branded healthcare and wellness products in Hong Kong, Macau, Mainland China, and internationally.

Sino Biopharmaceutical

Market Cap: HK$64.1b

An investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China.

Beijing Tong Ren Tang Chinese Medicine

Market Cap: HK$7.1b

Engages in the manufacture, retail, and wholesale of healthcare products and Chinese medicine to wholesalers and individuals.

SSY Group

Market Cap: HK$9.0b

An investment holding company, researches, develops, manufactures, trades in, and sells various pharmaceutical products to hospitals and distributors in the People’s Republic of China and internationally.

WuXi Biologics (Cayman)

Market Cap: HK$81.7b

An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia.

China Shineway Pharmaceutical Group

Market Cap: HK$5.7b

An investment holding company, engages in the research and development, manufacture, and trade of Chinese medicines in the People’s Republic of China and Hong Kong.

Shanghai Haohai Biological Technology

Market Cap: HK$12.3b

Shanghai Haohai Biological Technology Co., Ltd.

China Medical System Holdings

Market Cap: HK$17.5b

An investment holding company, manufactures, sells, markets, and promotes pharmaceutical products in the People’s Republic of China.